UPDATE: Synergy Pharma (SGYP) Higher on Linzess Approval (IRWD) (FRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
FDA Approves IBS-C Treatment Linzess (IRWD) (FRX)
August 30, 2012 11:05 AM EDTBelow is the FDA press release related to approval of Ironwood Pharmaceuticals' (NASDAQ: IRWD) and Forest Labs' (NYSE: FRX) Linzess:
Press Release:
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
According to the National Institutes of Health, an estimated 63 million people are affected by chronic constipation. Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and do not respond to standard... More
UPDATE: Ironwood (IRWD), Forest (FRX) Win FDA Approval for Linzess
August 30, 2012 10:58 AM EDT(Updated - August 30, 2012 10:59 AM EDT)
Ironwood Pharmaceuticals (NASDAQ: IRWD), Forest Labs (NYSE: FRX) win FDA approval for Linzess to treat irritable bowel. (NOTE: Shares of IRWD were halted)... More
